Immature human NT2 cells grafted into mouse brain differentiate into neuronal and glial cell types  by Ferrari, Alessandra et al.
Immature human NT2 cells grafted into mouse brain di¡erentiate into
neuronal and glial cell types
Alessandra Ferraria, Elisabeth Ehlerb, Roger M. Nitscha, Ju«rgen Go«tza;*
aDivision of Psychiatry Research, University of Zu«rich, August Forel Str. 1, 8008 Zurich, Switzerland
bInstitute of Cell Biology, ETH, Zurich, Switzerland
Received 2 October 2000; revised 6 November 2000; accepted 7 November 2000
First published online 24 November 2000
Edited by Guido Tettamanti
Abstract NT2 cells are a transfectable human embryonal
carcinoma cell line, that can be differentiated into postmitotic
neuron-like cells (NT2N cells), and transplanted into rodent
brains. Differentiation requires a 5-week-long treatment with
retinoic acid prior to transplantation. Here, we show that this
step can be omitted, and that undifferentiated NT2 cells migrate
over long distances and differentiate into both neuron- and
oligodendrocyte-like cell types upon grafting into brains of
immunocompetent newborn mice. Grafted cells can be traced by
fluorogold, with no evidence for tumor formation. Our approach
provides an experimental model system which allows the
immunohistological and biochemical study of neuronal and glial
differentiation of human cells in vivo, and which may be suitable
as an in vivo model for pharmacological studies. ß 2000 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
A common neuropathological feature of neurodegenerative
diseases is neuronal cell loss which is restricted to a particular
cell type in some diseases [1,2]. In Parkinson’s disease (PD),
for example, only the tyrosine hydroxylase neurons of the
substantia nigra are degenerating, whereas in other diseases
including Alzheimer’s disease (AD), several distinct neuronal
cell types in di¡erent brain areas are a¡ected. For the treat-
ment of these diseases, several approaches can be envisaged:
Whereas pharmacological treatment of PD with either L-3,4-
dihydroxyphenylalanine or dopamine agonists has been e¡ec-
tive to some extent, similar pharmacotherapies, such as the
use of cholinesterase inhibitors or muscarinic agonists, were
not very promising in AD. An alternative approach is cell
replacement therapy. For PD, clinical trials have already
been initiated by transplanting human fetal brain tissue in
order to substitute for the loss of dopaminergic neurons in
PD [3,4]. However, several aborted fetuses are required for the
therapy of a single patient. For practical and ethical reasons,
this approach is not very useful [5]. A third approach is the
use of engineered murine embryonal stem (ES) cells [6,7] or
human cell lines. One of the best established human cell lines
is the embryonal carcinoma cell line NTera-2 (in short NT2),
which is transfectable, capable of di¡erentiating into postmi-
totic neuron-like cells (NT2N cells) following treatment with
retinoic acid, and transplantable into brain or spinal cord of
immunocompetent and immunode¢cient rodents [8^10]. Intra-
cerebral grafting of NT2N cells has been successfully used to
promote functional recovery of ischemic rats [11]. However,
di¡erentiation of NT2 cells is an elaborate procedure [8]. Prior
to grafting, NT2 cells have to be incubated with retinoic acid
for at least 5 weeks, followed by three consecutive replatings,
in the presence of mitotic inhibitors, onto poly-D-lysin- and
laminin-coated dishes. As most of the NT2 cells di¡erentiate
into neurons under these conditions, they have been used as
replacement therapy for PD [12]. Neuronally di¡erentiated
NT2 cells (NT2N cells), grafted into athymic or immunosup-
pressed mice, survived for at least a year in the host brain
[13,14]. Undi¡erentiated NT2 cells, grafted into immunode¢-
cient mice, formed tumors [15] unless they were grafted into
the caudoputamen where the grafted cells remained and sur-
vived for up to a year [13]. They di¡erentiated into postmi-
totic neuron-like, but not glial-like, cell types [13].
In the present study, we show that £uorogold-labeled, un-
di¡erentiated NT2 cells can be grafted into immunocompetent
newborn mice (P0), without tumor formation. In addition,
many NT2 cells migrated over distances of several mm and
di¡erentiated not only into neuron-, but also glial-like cell
types.
2. Materials and methods
2.1. Cell culture
NT2 cells were obtained from Dr. Roland Brandt (Heidelberg) and
cultured as previously described [16]. Brie£y, cells were cultured in
Dulbecco’s modi¢ed Eagle’s medium (DMEM)^F12 medium (Gibco),
supplemented with 10% fetal calf serum (Seromed), 5% horse serum
(Seromed), and 1% penicillin/streptomycin (Gibco). Twice a week,
NT2 cells were split 1:5 onto uncoated tissue culture dishes. Two
days before grafting, the tracer substance £uorogold (Fluorochrome)
was diluted 1:10 000 in DMEM/F12 medium, incubated overnight at
37‡C, and added to NT2 cells for another day. Cells were washed ¢ve
times in phosphate-bu¡ered saline (PBS), trypsinized for 4 min at
37‡C, centrifuged at 900Ug for 5 min, taken up in PBS with a ¢nal
concentration of 50 000 cells/Wl, and kept on ice until grafting, for less
than 1 h. Primary embryonic day 18 (E18) neuronal cultures were
established from the cerebral cortices of C57BL/6UDBA/2 F1
(B6D2F1) mice following standard procedures and cultured on
poly-L-lysin-(Gibco) and ¢bronectin (Gibco)-coated coverslips in
MEM medium (Gibco) containing 4 g/l glucose (Sigma), 100 Wg/ml
transferrin (Sigma), 5 Wg/ml insulin (Sigma), 20 nM progesterone
(Sigma), 100 WM putrescine (Sigma), 30 nM selendioxide (Sigma),
1 mM sodium pyruvate (Sigma), 0.1% ovalbumin (Sigma) and 5 WM
AraC (Sigma), for 8 days prior to staining.
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2.2. Transplantation
Immunocompetent C57BL/6UDBA/2 F1 (B6D2F1) females were
obtained from Biological Research Laboratories, and kept in a con-
ventional animal facility. They were hormonally stimulated with 5 U
PMS gonadotropin (Folligon, Intervet) at day 33, 5 U HCG gona-
dotropin (Chorulon, Intervet) at day 31, and mated with B6D2F1
males as described [17]. Immediately after birth, the newborn mice
(P0) were placed on a pre-warmed glass plate, and injected intracer-
ebrally into or close to the ventricle with approximately 1 Wl of NT2
cells in PBS, using a glass capillary. This capillary had an outer diam-
eter of 50^100 Wm and was plugged into a tube, with a mouth piece
inserted at the other end of the tube. In order to monitor the grafting
procedure, some of the injected NT2 aliquots were mixed with bro-
mophenol blue or trypan blue. Immunohistochemistry was done with
at least six grafted animals per experiment, and stainings were done in
duplicate for every grafted mouse brain. The transplanted cells were
monitored at days P1, P7, P14 and P21 after grafting. Approximately
100 sections were obtained from each grafted brain, of which, at days
P14 and P21, between 20 and 30 contained substantial numbers of
grafted cells. Immunohistochemical stainings were done with three
sections each per antibody.
2.3. Immunohistochemistry
Antibody MAB353 (Chemicon, used at 1:200 dilutions) was used to
detect nestin; anti-glial ¢brillary acidic protein (GFAP) antibody AM-
2185-11 (InnoGenex, used at 1:1000 dilutions) was used to detect
astrocytes, anti-CNPase antibody AM-2033-11 (InnoGenex, used at
1:500 dilutions) was used to detect oligodendrocytes, anti-MAP-2
antibody (Roche, # 1284959, used at 1:500 dilutions) was used to
detect neurons, anti-EndoA antibody Troma-1 [18] was used to detect
cytokeratins, and anti-FG antibody (Fluorochrome, 1:5000) was used
to detect the £uorogold-labeled human NT2 cells. As secondary anti-
bodies, £uorescein isothiocyanate (FITC)- and Cy3-labeled anti-
mouse and anti-rabbit IgG antibodies (Molecular Probes) were used
at 1:1000 dilutions.
Cultures of NT2 cells and frontal vibratome sections (30^50 Wm
thick) of mouse brain were incubated with antibodies directed against
£uorogold and di¡erentiation markers, and analyzed by confocal or
conventional £uorescence microscopy. For confocal analyses, sections
were washed and mounted in 0.1 M Tris^HCl (pH 9.5)/glycerol (3:7)
including 50 mg/ml n-propyl gallate as anti-fading reagent [19]. Sec-
tions were viewed by using a Leica TCS confocal microscope, and
images were processed with the IMARIS software package (Bitplane).
To estimate the survival of grafted cells, vibratome sections were
viewed in the UV channel of a conventional £uorescence microscope.
NT2 and primary cell cultures were ¢xed in 4% paraformaldehyde in
PBS for 10 min at room temperature and stained as described pre-
viously [20].
3. Results
3.1. Characterization of undi¡erentiated NT2 cells in culture
To determine the di¡erentiation capacity of NT2 cells after
grafting into mouse brain, we analyzed undi¡erentiated NT2
cells in culture, before grafting, by immunohistochemistry
(Fig. 1). We found that approximately 60^70% of the NT2
cells expressed epithelial cell-speci¢c cytokeratin as revealed
with antibody Troma1 [18] (Fig. 1A), whereas typical neuro-
nal and glial di¡erentiation markers, such as MAP-2 for neu-
rons, CNPase for oligodendrocytes, and GFAP for astrocytes,
were negative at this stage of culture (Fig. 1C^E). The inter-
mediate ¢lament protein nestin, which is a marker for neuro-
glial progenitor cells committed to neuronal cell fate [21], was
expressed in approximately 20^30% of the NT2 cells, demon-
strating heterogeneity of the NT2 cell culture (Fig. 1B). As a
negative control, the primary antibody was omitted from the
reaction (Fig. 1F).
Fig. 1. Cultured NT2 cells express epithelial cell-speci¢c cytokeratins
(A). The intermediate ¢lament protein nestin is expressed by ap-
proximately 20^30% of the NT2 cells (B). Di¡erentiation markers,
such as MAP-2 for neurons, CNPase for oligodendrocytes, and
GFAP for astrocytes, are not expressed (C^E). A negative control is
included where the primary antibody has been omitted (F). Scale
bar: 100 Wm.
Fig. 2. Cortical primary neurons obtained from mouse brain are
not stained by the endothelial cell-speci¢c antibody Troma-1 or an
antibody directed against the neural progenitor marker nestin (A,
B). Cultures express the neuronal marker MAP-2 (C), but not the
oligodendrocytic marker CNPase (D). Astrocytes were also detected,
as indicated by GFAP staining (E). A negative control is included
where the primary antibody has been omitted (F). Scale bar: 100
Wm.
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3.2. Characterization of primary neuronal cultures
In order to compare the di¡erentiation potential of grafted
NT2 cells to primary neuronal cultures, cortical primary neu-
rons obtained from mouse brain were analyzed immunohisto-
chemically after 8 days in culture (Fig. 2). Primary neuronal
cultures did not express cytokeratins as shown with epithelial
cell-speci¢c antibody Troma-1 (Fig. 2A). However, they ex-
pressed the neuronal marker MAP-2 (Fig. 2C), but not the
neural progenitor marker nestin or the oligodendrocytic
marker CNPase (Fig. 2B,D). Cultures were stained by an anti-
body directed against GFAP re£ecting the presence of astro-
cytes (Fig. 2E). As a negative control, the primary antibody
was omitted from the reaction (Fig. 2F).
3.3. Survival and morphology of undi¡erentiated NT2 cells
grafted into mouse brain
Undi¡erentiated NT2 cells were preincubated with £uoro-
gold for 1 day, washed and grafted intracerebrally into new-
born (P0) mice. Mice were sacri¢ced and brains analyzed at
postnatal days P1, P7, P14 and P21, respectively. Between
days P1 and P7 after grafting, the £uorogold-labeled NT2
cells clustered around the injection site. After day P7, the
majority of surviving NT2 cells started to migrate from the
injection site along the surface of the lateral ventricle, follow-
ing myelinated ¢bers, in particular of the corpus callosum, to
the contralateral hemisphere (Fig. 3A,B). Until day P21, some
of the grafted cells even migrated over distances of several
mm. At that time, at least 1% of the injected cells had sur-
vived, and the remaining cells showed cell shrinkage and nu-
clear condensation most likely re£ecting apoptotic mecha-
nisms. The histological analysis did not provide any
evidence for tumor formation or pathological abnormalities.
3.4. In situ di¡erentiation of undi¡erentiated NT2 cells grafted
into mouse brain
Between P14 and P21 after grafting, £uorogold-positive
cells changed their morphology and lost their round shape
(Fig. 3C). At least three di¡erent types of morphologies
were found: £attened cells with relatively few processes, bipo-
lar cells and cells with a rich arborization (Fig. 3C^F).
Vibratome sections of grafted brains were costained with
antibodies directed against £uorogold and di¡erentiation
markers, and analyzed by confocal microscopy (Fig. 4). At
days P7 until P14 after grafting, we identi¢ed £uorogold-pos-
itive NT2 cells which had retained nestin expression (Fig. 4K^
M). At days P18 until P21, some of the NT2 cells expressed
neuronal markers as indicated by MAP-2 staining (Fig. 4A^
F). The morphology was similar to a neuronal arborization
(Fig. 4D^F) or a bipolar morphology (Fig. 4A^C). In addi-
tion, another subset of grafted NT2 cells were identi¢ed which
Fig. 3. Upon intraventricular grafting into P0 mouse brain, undi¡erentiated £uorogold-labeled NT2 cells migrate and undergo morphological
changes. Between days P1 and P7 after grafting, the £uorogold-labeled NT2 cells form a mass of cells clustered around the injection site (A).
Subsequently, cells start to migrate and are found, at day P21 after grafting, several mm distant from the injection site, along the corpus callos-
um (CC) and the lining of both ventricles (Ve) (B). Between P14 and P21 after grafting, NT2 cells lose their round shape (C) and acquire dif-
ferent types of morphologies: £attened cells with relatively few processes, bipolar cells and cells with a rich arborization (D^F). Scale bar:
A, 250 Wm; B, 100 Wm; C, 25 Wm; D^F, 10 Wm.
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belonged to the oligodendrocytic cell lineage as shown by
expression of the CNPase marker (Fig. 4G^I). We could not
identify any GFAP-positive NT2 cell in the grafted brain in-
dicating that NT2 cells did not di¡erentiate into cells of the
astrocytic cell lineage (Fig. 4Q^S). Also, we did not identify
NT2 cells that had di¡erentiated into endothelial-like cells, as
shown by the absence of Troma-1 reactivity (Fig. 4N^P).
4. Discussion
Our study shows that undi¡erentiated human NT2 embry-
onal carcinoma cells migrate over distances of up to 5 mm
and di¡erentiate into neuron- and glial-like cell types upon
grafting into brains of newborn (P0) immunocompetent
mice, with no evidence for tumor formation.
4.1. Di¡erentiation potential of grafted NT2 cells
It has previously been shown that undi¡erentiated NT2
cells in culture expressed cytokeratins as predominant inter-
mediate ¢lament protein, and that only a fraction of cells
expressed vimentin, and none expressed GFAP or neuro¢la-
ment chains [16]. Immature NT2 cells never went on to estab-
lish polarized neurites with the characteristics of axons or
dendrites as evidenced by either the distribution of cytoskele-
tal markers (such as MAP-2) or by functional assays
[16,22,23]. We con¢rmed these published characteristics for
the batch of NT2 cells which was used for our grafting experi-
ments, and included CNPase as marker for oligodendrocytes
(Figs. 1 and 2). Undi¡erentiated NT2 cells in culture ex-
pressed nestin and cytokeratins, but no neuronal, astrocytic
or oligodendrocytic markers. Grafting into newborn (P0) im-
munocompetent mice was not accompanied by tumor forma-
tion. It has been shown previously that the caudoputamen
(CP) of immunode¢cient nude mice speci¢cally inhibits pro-
liferation of NT2 cells grafted into the CP [13], although the
NT2 cells formed lethal tumors following grafting into periph-
eral tissues and into many regions of the nude mouse central
nervous system [15]. This suggests that endogenous factors
modulate cell proliferation and di¡erentiation, and that the
P0 immunocompetent brain used in our studies is similar to
the CP of adult nude mice, with respect to tumor formation.
Grafting into P0 immunocompetent mice induced di¡erentia-
tion not only into neuron-, but also oligodendrocyte-like cells.
Some NT2 cells retained nestin expression, but did not express
cytokeratins, which indicates that these cells had initiated dif-
ferentiation without ¢nal commitment to either the neuronal
or glial cell lineage (Fig. 4). In contrast, grafting of undi¡er-
entiated NT2 cells into the caudoputamen of immunode¢cient
adult mice only induced di¡erentiation into neuron-like cells
[13]. Intrauterine transplantation of murine ES cells into brain
generated neural chimeras composed of ES cell-derived neu-
rons, oligodendrocytes and astrocytes [7,24]. This suggests
that the P0 brain produces the cues for neuronal and oligo-
dendrocytic di¡erentiation of NT2 cells, and that immature
NT2 cells have the potential to di¡erentiate into neuron- and
oligodendrocyte-like cells. It remains to be established
whether intrauterine injections into embryonic mouse brain
of immature NT2 cells induces astrocytic di¡erentiation, as
in the case of murine ES cells.
A major advantage of the present grafting approach is that
grafted NT2 cells can be discriminated from murine brain
cells by £uorogold labeling, and that the state of di¡erentia-
tion can be monitored by expression of di¡erentiation anti-
gens. Therefore, this approach is suited also to biochemical
characterization of NT2 di¡erentiation in situ. Grafted cells
either can be isolated by £uorescence-activated cell sorting or
Fig. 4. Confocal microscopy reveals that immature NT2 cells
grafted into mouse brain are capable to di¡erentiate into neuronal
and glial cell types. Vibratome sections of grafted brains are co-
stained with antibodies directed against £uorogold, to identify NT2
cells (¢rst column, Cy3 channel), and di¡erentiation markers (sec-
ond column, FITC channel). Stainings were done with antibodies
directed against MAP-2 (A^F), CNPase (G^I), nestin (K^M), cyto-
keratin (N^P) and GFAP (Q^S). The overlay (third column) reveals
MAP-2-, CNPase- and nestin-positive NT2 cells, respectively. Scale
bar: 10 Wm.
FEBS 24351 4-12-00 Cyaan Magenta Geel Zwart
A. Ferrari et al./FEBS Letters 486 (2000) 121^125124
by UV-laser dissection methods of single cells from endoge-
nous tissue [25] at various time points after grafting, sorted
according to their di¡erentiation state, and subjected to di¡er-
ential screenings to identify mRNAs whose expression levels
are altered during di¡erentiation. Alternatively, gene expres-
sion can be monitored as a function of time and di¡erentia-
tion using microarray techniques [25].
4.2. Migration and survival of grafted NT2 cells
We showed in our study that NT2 cells migrated from the
ventricle along the corpus callosum and ventricular lining to
the contralateral hemisphere, for as far as 5 mm (Fig. 3B).
Migration of neuronally di¡erentiated NT2 (NT2N) cells
grafted into adult brain, in contrast, depended on the site of
integration: NT2N cells grafts introduced into the septum
were dispersed over a relatively wide area (several mm) within
the septum, while grafts which were introduced into the neo-
cortex were completely con¢ned within the neocortex [14].
Murine ES cells, grafted intrauterinely, migrated over distan-
ces of several mm. This suggests that migration of grafted cells
(NT2 or ES cells) is mainly determined by the age and ma-
turity of the host brain.
4.3. Reconstructive approaches in the nervous system:
deterministic versus non-cell-autonomous concepts
Transplantation is one of the most e¡ective strategies for
restoring cell loss and tissue function. Widely used in a variety
of organ systems, transplantation approaches in the nervous
system are still in their infancy. The complexity of the tissue
and our limited knowledge about the mechanisms required for
neuronal integration have restricted therapeutic e¡orts to re-
constitute local, well characterized neurotransmitter de¢cits,
such as restoring the nigrostriatal dopaminergic system in
PD patients. Such an approach puts a lot of emphasis on
the donor cell population, and a considerable e¡ort in the
transplantation ¢eld is still directed at establishing and im-
proving dopaminergic donor cells. Although this deterministic
strategy has been used successfully for PD patients, such a
strategy is not useful for the treatment of more widespread
neurodegenerative diseases, and non-cell-autonomous con-
cepts provide a more promising perspective. These concepts
emphasize the plasticity of individual precursor cells and re-
gard region-speci¢c di¡erentiation as a response of pluripo-
tent precursor cells to local environmental cues [3].
The ¢nding, that even undi¡erentiated NT2 cells, which can
be grown in high quantities, do di¡erentiate into neuron- and
oligodendrocyte-like cells, emphasizes the usefulness of NT2
cells in therapeutic approaches. NT2 cells are particularly val-
uable as they may be used as vehicles for the release of neuro-
trophic factors into the host brain environment. In addition,
our approach provides an experimental model system which
allows the study of neuronal and glial di¡erentiation of hu-
man cells in vivo, and which may be suitable as an in vivo
model for pharmacological studies. Moreover, a comparative
analysis of the caudoputamen of adult nude mice and the
immature brain of newborn immunocompetent mice may pro-
vide insights into inductive mechanisms of the host brain that
make possible both the inhibition of proliferation and the
induction of NT2 cell di¡erentiation into postmitotic neuron-
and glial-like cells in situ.
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